CoChat

Abrupt Discontinuation Compared With a 1-Week Taper Regimen in Depressed Outpatients Treated for 24 Weeks With Desvenlafaxine 50 mg/d

Khan, Arif, Musgnung, Jeff, Ramey, Tanya, Messig, Michael, Buckley, Gina, Ninan, Philip T. · 2014 · Journal of Clinical Psychopharmacology

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

The objective of this study was to determine whether the occurrence of discontinuation symptoms was equivalent for abrupt discontinuation versus 1-week taper to desvenlafaxine 25 mg/d after a 24-week treatment with desvenlafaxine 50 mg/d (administered as desvenlafaxine succinate) for major depressive disorder. Adult outpatients with major depressive disorder who completed the 24 weeks of open-label treatment with desvenlafaxine 50 mg/d were randomly assigned to no discontinuation (desvenlafaxine 50 mg/d), taper (desvenlafaxine 25 mg/d), or abrupt discontinuation (placebo) groups for the double-blind (DB) taper phase. The primary end point was Discontinuation-Emergent Signs and Symptoms (DESS) scale total score during the first 2 weeks of the DB phase. The null hypothesis that the absolute difference of greater than 2.5 in DESS scores between taper and abrupt discontinuation groups was tested by calculating the 95% 2-sided confidence interval on the mean difference between the 2 groups. Of the 480 patients enrolled in the open-label phase, 357 (≥1 postrandomization DESS record) were included in the primary analysis. Adjusted mean ± SE DESS scores were 4.1 ± 0.72 for no discontinuation (n = 72), 4.8 ± 0.54 for taper (n = 139), and 5.3 ± 0.52 for abrupt discontinuation (n = 146) groups. The difference in adjusted mean DESS total scores between the abrupt discontinuation and taper groups was 0.50 (95% confidence interval, -0.88 to 1.89) within the prespecified margin (±2.5) for equivalence. The number of patients who discontinued because of adverse events or discontinuation symptoms during the DB period was similar between the taper (2.8%) and abrupt discontinuation (2.1%) groups. These findings indicate that an abrupt discontinuation of desvenlafaxine 50 mg/d produces statistically equivalent DESS scores compared with the 1-week taper using 25 mg/d.

Overview

Integrity signals

Registry

Crossref · 10.1097/jcp.0000000000000100

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

11 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 14 references

Cited by

See all 30

Metadata

Authors
Khan, A., Musgnung, J., Ramey, T., Messig, M., Buckley, G., & Ninan, P. T.
Affiliations
  • Duke University (US)
  • Pfizer (United States) (US)
Corresponding author
Khan, Arif
Venue
Journal of Clinical Psychopharmacology
Published
2014-06
Volume
34
Issue
3
Pages
365-368
ISSN
0271-0749 (ISSN-L)
OpenAlex
W1998296507
Cited by
30
References
14
Citations by year
2025: 2 · 2024: 3 · 2023: 5 · 2022: 2 · 2021: 4 · 2020: 2 · 2019: 5 · 2018: 4 · 2015: 1 · 2014: 2
FWCI
0.73
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords
desvenlafaxine, abrupt discontinuation, dose tapering, major depressive disorder, outpatients
MeSH terms
Desvenlafaxine Succinate, Adult, Antidepressive Agents, Cyclohexanols, Major Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Humans, Outpatients, Substance Withdrawal Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Abrupt Discontinuation Compared With a 1-Week Taper Regimen in Depressed Outpatients Treated for 24 Weeks With Desvenlafaxine 50 mg/d. https://app.cochat.ai/papers/10.1097/jcp.0000000000000100
The paper
Khan, A., Musgnung, J., Ramey, T., Messig, M., Buckley, G., & Ninan, P. T. (2014). Abrupt Discontinuation Compared With a 1-Week Taper Regimen in Depressed Outpatients Treated for 24 Weeks With Desvenlafaxine 50 mg/d. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000000100

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.